Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...

Antibody-drug conjugates, a well-established antitumor strategy, are used for targeted delivery of cytotoxic drugs through antibodies. As cancer research progresses, other technologies with different ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

March 04, 2025 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) therapeutics ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

For example, antibody-drug conjugates use targeted antibodies to deliver highly cytotoxic drugs directly to tumor sites, while receptor ligand peptides armed with MRI agents improve medical imaging.

Less than a month after unveiling a peptide expansion at its production ... manufacturing workshop tipped to speed its antibody-drug conjugate (ADC) production timelines for clients.

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide-drug conjugate (PDC) ...